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a b s t r a c t
The transcription factor NF-E2 p45-related factor 2 (Nrf2; gene name NFE2L2) allows adaptation and
survival under conditions of stress by regulating the gene expression of diverse networks of
cytoprotective proteins, including antioxidant, anti-inﬂammatory, and detoxiﬁcation enzymes as well
as proteins that assist in the repair or removal of damaged macromolecules. Nrf2 has a crucial role in the
maintenance of cellular redox homeostasis by regulating the biosynthesis, utilization, and regeneration
of glutathione, thioredoxin, and NADPH and by controlling the production of reactive oxygen species by
mitochondria and NADPH oxidase. Under homeostatic conditions, Nrf2 affects the mitochondrial
membrane potential, fatty acid oxidation, availability of substrates (NADH and FADH2/succinate) for
respiration, and ATP synthesis. Under conditions of stress or growth factor stimulation, activation of Nrf2
counteracts the increased reactive oxygen species production in mitochondria via transcriptional
upregulation of uncoupling protein 3 and inﬂuences mitochondrial biogenesis by maintaining the levels
of nuclear respiratory factor 1 and peroxisome proliferator-activated receptor γ coactivator 1α, as well as
by promoting purine nucleotide biosynthesis. Pharmacological Nrf2 activators, such as the naturally
occurring isothiocyanate sulforaphane, inhibit oxidant-mediated opening of the mitochondrial perme-
ability transition pore and mitochondrial swelling. Curiously, a synthetic 1,4-diphenyl-1,2,3-triazole
compound, originally designed as an Nrf2 activator, was found to promote mitophagy, thereby
contributing to the overall mitochondrial homeostasis. Thus, Nrf2 is a prominent player in supporting
the structural and functional integrity of the mitochondria, and this role is particularly crucial under
conditions of stress.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Introduction
The transcription factor NF-E2 p45-related factor 2 (Nrf2; gene
name NFE2L2) regulates the expression of networks of genes
encoding proteins with diverse cytoprotective activities. Nrf2 itself
is controlled primarily at the level of protein stability. Under basal
conditions, Nrf2 is a short-lived protein that is subjected to
continuous ubiquitination and proteasomal degradation. There
are three known ubiquitin ligase systems that contribute to the
degradation of Nrf2. Historically, the ﬁrst negative regulator of
Nrf2 to be discovered was Kelch-like ECH-associated protein 1
(Keap1) [1], a substrate adaptor protein for Cullin 3 (Cul3)/Rbx1
ubiquitin ligase [2–4]. Keap1 uses a highly efﬁcient cyclic mechan-
ism to target Nrf2 for ubiquitination and proteasomal degradation,
during which Keap1 is continuously regenerated, allowing the
cycle to proceed (Fig. 1A) [5]. Nrf2 is also subjected to degradation
mediated by glycogen synthase kinase (GSK)3/β-TrCP-dependent
Cul1-based ubiquitin ligase [6,7]. Most recently, it was reported
that, during conditions of endoplasmic reticulum stress, Nrf2 is
ubiquitinated and degraded in a process mediated by the E3
ubiquitin ligase Hrd1 [8].
In addition to serving as a ubiquitin ligase substrate adaptor
protein, Keap1 is also the sensor for a wide array of small-molecule
activators of Nrf2 (termed inducers) [9]. Inducers block the cycle of
Keap1-mediated degradation of Nrf2 by chemically modifying speciﬁc
cysteine residues within Keap1 [10,11] or by directly disrupting the
Keap1:Nrf2 binding interface [12,13]. Consequently, Nrf2 is not
degraded, and the transcription factor accumulates and translocates
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Fig. 1. The cyclic sequential binding and regeneration model for Keap1-mediated degradation of Nrf2. (A) Nrf2 binds sequentially to a free Keap1 dimer: ﬁrst through its
high-afﬁnity ETGE (red sticks) binding domain and then through its low-afﬁnity DLG (black sticks) binding domain. In this conformation of the protein complex, Nrf2
undergoes ubiquitination and is targeted for proteasomal degradation. Free Keap1 is regenerated and able to bind to newly translated Nrf2, and the cycle begins again.
(B) Inducers (white diamonds) react with sensor cysteines of Keap1 (blue sticks), leading to a conformational change and impaired substrate adaptor activity. Free Keap1 is
not regenerated, and the newly synthesized Nrf2 accumulates and translocates to the nucleus.
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to the nucleus (Fig. 1B), where it forms a heterodimer with a small Maf
protein; binds to antioxidant-response elements, the upstream reg-
ulatory regions of its target genes; and initiates transcription [14–16].
The battery of Nrf2 targets comprises proteins with diverse cytopro-
tective functions, including enzymes of xenobiotic metabolism,
proteins with antioxidant and anti-inﬂammatory functions, and pro-
teasomal subunits, as well as proteins that regulate cellular redox
homeostasis and participate in intermediary metabolism.
Nrf2, a master regulator of cellular redox homeostasis
The function of Nrf2 as a master regulator of cellular redox
homeostasis is widely recognized. The gene expression of both the
catalytic and the regulatory subunits of γ-glutamyl cysteine ligase,
the enzyme catalyzing the rate-limiting step in the biosynthesis of
reduced glutathione (GSH), is directly regulated by Nrf2 [17]. The
xCT subunit of system xc-, which imports cystine into cells, is also a
direct transcriptional target of Nrf2 [18]. In the cell, cystine
undergoes conversion to cysteine, a precursor for the biosynthesis
of GSH. In addition to its role in GSH biosynthesis, Nrf2 provides
the means for the maintenance of glutathione in its reduced state
by the coordinated transcriptional regulation of glutathione reduc-
tase 1 [19,20], which reduces oxidized glutathione to GSH using
reducing equivalents from NADPH. The required NADPH is pro-
vided by four principal NADPH-generating enzymes, malic enzyme
1 (ME1), isocitrate dehydrogenase 1 (IDH1), glucose-6-phosphate
dehydrogenase (G6PD), and 6-phosphogluconate dehydrogenase
(PGD), all of which are transcriptionally regulated in part by Nrf2
(Fig. 2) [21–24]. Curiously, Nrf2 also regulates the inducible gene
expression of the cytosolic, microsomal, and mitochondrial forms
of aldehyde dehydrogenase [25], which use NAD(P)þ as a cofactor,
giving rise to NAD(P)H. Indeed, the levels of NADPH and the
NADPH/NADPþ ratio are lower in embryonic ﬁbroblasts isolated
from Nrf2-knockout (Nrf2-KO) mice compared to cells from their
wild-type (WT) counterparts, and the NADPH levels decrease upon
Nrf2 knockdown in cancer cell lines with constitutively active Nrf2
[26]. As expected, the levels of GSH are lower in cells in which
Nrf2 has been disrupted; conversely, Nrf2 activation by genetic
or pharmacological means leads to GSH upregulation [27–29].
Importantly, Nrf2 also regulates the gene expression of thiore-
doxin [30–32], thioredoxin reductase 1 [28,29,32,33], and sulﬁr-
edoxin [34], which are essential for the reduction of oxidized
protein thiols.
Given the crucial role of Nrf2 as a master regulator of cellular redox
homeostasis, it is not surprising that, compared to WT cells, the levels
of reactive oxygen species (ROS) are higher in cells in which Nrf2 has
been disrupted (Nrf2-KO) [35]. This difference is particularly striking
upon challenge with agents causing oxidative stress. Moreover, cells
deﬁcient in Nrf2 are much more sensitive to the toxicity of oxidants of
various types and cannot be protected by Nrf2 inducers, which, under
the same conditions, provide efﬁcient and long-lasting protection to
WT cells [29,36,37]. In addition to the overall cellular redox home-
ostasis, Nrf2 is also critical for the maintenance of the mitochondrial
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Fig. 2. The role of Nrf2 in the metabolism of rapidly proliferating cells. Nrf2 is a positive regulator of genes encoding enzymes in both the oxidative arm [i.e., glucose-6-
phosphate dehydrogenase (G6PD) and 6-phosphogluconate dehydrogenase (PGD)] and the nonoxidative arm [i.e., transaldolase 1 (TALDO1) and transketolase (TKT)] of the
pentose phosphate pathway. G6PD and PGD generate NADPH. Nrf2 also regulates the gene expression of the other two NADPH-generating enzymes, malic enzyme 1 (ME1)
and isocitrate dehydrogenase 1 (IDH1). The gene expression of phosphoribosyl pyrophosphate amidotransferase (PPAT), which catalyzes the entry into the de novo purine
biosynthetic pathway, is also positively regulated by Nrf2, as is the expression of methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), a mitochondrial enzyme with a
critical role in providing one-carbon units for de novo purine biosynthesis. Pyruvate kinase (PK) is negatively regulated by Nrf2 and is expected to favor the buildup of
glycolytic intermediates and, together with G6PD, metabolite channeling through the pentose phosphate pathway and the synthesis of nucleic acids, amino acids, and
phospholipids. Nrf2 negatively regulates the gene expression of ATP-citrate lyase (CL), which may increase the availability of citrate for mitochondrial utilization or (through
isocitrate) for IDH1. Red and blue indicate positive and negative regulation, respectively. The mitochondrion is shown in gray. Metabolite abbreviations: G-6-P, glucose 6-
phosphate; F-6-P, fructose 6-phosphate; F-1,6-BP, fructose 1,6-bisphosphate; GA-3-P, glyceraldehyde 3-phosphate; 3-PG, 3-phosphoglycerate; PEP, phosphoenolpyruvate;
6-P-Gl, 6-phosphogluconolactone; 6-PG, 6-phosphogluconate; R-5-P, ribulose 5-phosphate; PRPP, 5-phosphoribosyl-α-1-pyrophosphate; THF, tetrahydrofolate; IMP, inosine
monophosphate; AMP, adenosine monophosphate; GMP, guanosine monophosphate.
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redox homeostasis. Thus, compared to WT, the total mitochondrial
NADH pool is signiﬁcantly increased in Keap1-KO and dramatically
decreased in Nrf2-KO cells [35].
Using live cell imaging, we recently monitored the rates of ROS
production in primary glioneuronal cocultures and brain tissue
slices isolated from WT, Nrf2-KO, or Keap1-knockdown (Keap1-
KD) mice [38]. As expected, the rate of ROS production was faster
in Nrf2-KO cells and tissues compared to their WT counterparts.
However, we made the unexpected observation that, compared to
WT, Keap1-KD cells also have higher rates of ROS production,
although the magnitude of the difference between the WT and the
Keap1-KD genotypes was smaller than that between WT and Nrf2-
KO. We then analyzed the mRNA levels of NOX2 and NOX4, the
catalytic subunits of the two NADPH oxidase (NOX) isoforms that
have been implicated in brain pathology, and found that NOX2 is
dramatically increased under conditions of Nrf2 deﬁciency,
whereas NOX4 is upregulated when Nrf2 is constitutively acti-
vated, although to a smaller extent. Quantitatively, the magnitude
of upregulation in cells and tissues from the mutant mice parallels
the corresponding increases in ROS production [38]. Interestingly,
not only does Nrf2 regulate NADPH oxidase, but the ROS produced
by NADPH oxidase can activate Nrf2, as shown in pulmonary
epithelial cells and cardiomyocytes [39,40]. Furthermore, a very
recent study has demonstrated that the NADPH oxidase-
dependent activation of Nrf2 constitutes an important endogenous
mechanism for protection against mitochondrial damage and cell
death in the heart during chronic pressure overload [41].
In addition to the catalytic activity of NADPH oxidase, mito-
chondrial respiration is another major intracellular source of ROS.
By use of the mitochondria-speciﬁc probe MitoSOX, we have
examined the contribution of ROS of mitochondrial origin to the
overall ROS production in primary glioneuronal cocultures isolated
from WT, Nrf2-KO, or Keap1-KD mice [38]. As expected, Nrf2-KO
cells had higher rates of mitochondrial ROS production than WT.
In agreement with the ﬁndings for the overall ROS production, the
rates of mitochondrial ROS production in Keap1-KD were also
higher compared to WT cells. Importantly, blocking complex I with
rotenone caused a dramatic increase in mitochondrial ROS pro-
duction in both WT and Keap1-KD cells, but had no effect in Nrf2-
KO cells. In contrast to the expected increase in mitochondrial ROS
production in WT cells after addition of pyruvate (to enhance the
availability of NADH, increase the mitochondrial membrane poten-
tial,and normalize respiration), the production of ROS decreased in
Nrf2-KO cells. Together, these ﬁndings strongly suggest that, in the
absence of Nrf2: (i) the activity of complex I is impaired, (ii) the
impaired activity of complex I is due to limitation of substrates,
and (iii) the impaired activity of complex I is one of the main
reasons for the increased mitochondrial ROS production, possibly
owing to reverse electron ﬂow from complex II.
Nrf2 affects mitochondrial membrane potential and
respiration
The mitochondrial membrane potential (Δψm) is a universal
indicator of mitochondrial health and the metabolic state of the
cell. In a healthy cell, Δψm is maintained by the mitochondrial
respiratory chain. Interestingly, a stable isotopic labeling with
amino acids in culture-based proteomics study in the estrogen
receptor-negative nontumorigenic human breast epithelial
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lower NADPH levels. (2) The levels of GSH are also low. (3) The low activity of ME1 may decrease the pool of pyruvate entering the mitochondria. (4) The generation of NADH
is slower, leading to impaired activity of complex I and increased mitochondrial ROS production. (5) The reduction of FAD to FADH2 in mitochondrial proteins is also
decreased, lowering the electron ﬂow from FADH2 to UbQ and into complex III. (6) The slower formation of UbQH2 may lower the enzyme activity of succinate
dehydrogenase. (7) The increased levels of ROS may further inhibit the activity of complex II. (8) The lower efﬁciency of fatty acid oxidation contributes to the decreased
substrate availability for mitochondrial respiration. (9) Glycolysis is enhanced as a compensatory mechanism for the decreased ATP production in oxidative phosphorylation.
(10) ATP synthase operates in reverse to maintain Δψm. Red and blue indicate upregulation and downregulation, respectively. The boxes signify availability of experimental
evidence. The inset shows images of mitochondria of WT and Nrf2-KO cortical astrocytes visualized by the potentiometric ﬂuorescent probe tetramethylrhodamine methyl
ester (TMRM; 25 nM). Scale bar, 20 mm.
A.T. Dinkova-Kostova, A.Y. Abramov / Free Radical Biology and Medicine 88 (2015) 179–188182
MCF10A cell line has shown that the mitochondrial electron
transport chain component NDUFA4 is upregulated by pharmaco-
logical activation (by sulforaphane) of Nrf2, whereas genetic
upregulation of Nrf2 (by Keap1 knockdown) leads to downregula-
tion of the cytochrome c oxidase subunits COX2 and COX4I1 [42].
A study of the liver proteome using two-dimensional gel electro-
phoresis and matrix-assisted laser desorption/ionization mass
spectrometry has found that Nrf2 regulates the expression of
ATP synthase subunit α [43]. In addition, the mitochondrial
protein DJ-1, which plays a role in the maintenance of the activity
of complex I [44], has been reported to stabilize Nrf2 [45,46],
although the neuroprotective effects of pharmacological or genetic
activation of Nrf2 are independent of DJ-1 [47]. However, the
consequences of these observations for mitochondrial function
have not been investigated.
In agreement with the impaired activity of complex I under
conditions of Nrf2 deﬁciency, the basal Δψm is lower in Nrf2-KO
mouse embryonic ﬁbroblasts (MEFs) and cultured primary glio-
neuronal cells in comparison with their WT counterparts (Fig. 3,
inset) [35]. In contrast, the basal Δψm is higher when Nrf2 is
genetically constitutively upregulated (by knockdown or knockout
of Keap1). These differences in Δψm among the genotypes
indicate that respiration is affected by the activity of Nrf2. Indeed,
evaluation of the oxygen consumption in the basal state has
revealed that, compared to WT, the oxygen consumption is lower
in Nrf2-KO and Keap1-KO MEFs, by 50 and 35%, respectively.
These differences inΔψm and respiration among the genotypes
are reﬂected by the rate of utilization of substrates for mitochon-
drial respiration. Application of substrates for the tricarboxylic
acid (TCA) cycle (malate/pyruvate, which in turn increase the
production of the complex I substrate NADH) or methyl succinate,
a substrate for complex II, causes a stepwise increase in Δψm in
both WT and Keap1-KD neurons, but the rate of increase is higher
in Keap1-KD cells. More importantly, the shapes of the response to
these TCA cycle substrates are different between the two geno-
types, whereby the rapid rise in Δψm in Keap1-KD cells upon
substrate addition is followed by a quick drop rather than a
plateau, suggesting an unusually fast substrate consumption.
These ﬁndings are in close agreement with the much lower (by
50–70%) levels of malate, pyruvate, and succinate that have been
observed after a 1-h pulse of [U-13C6]glucose in Keap1-KO com-
pared to WT MEF cells [24]. In Nrf2-KO neurons, only pyruvate is
able to increase the Δψm, whereas malate and methyl succinate
cause mild depolarization. The effect of Nrf2 on mitochondrial
substrate production seems to be the main mechanism by which
Nrf2 affects mitochondrial function. The mitochondrial NADH
redox index (the balance between consumption of NADH by
complex I and production of NADPH in the TCA cycle) is signiﬁ-
cantly lower in Nrf2-KO cells in comparison with their WT
counterparts, and furthermore, the rates of regeneration of the
pools of NADH and FADH2 after inhibition of complex IV (by use of
NaCN) are slower in the mutant cells.
In mitochondria isolated from murine brain and liver, supple-
mentation of substrates for complex I or for complex II increases
the rate of oxygen consumption more strongly when Nrf2 is
activated and less efﬁciently when Nrf2 is disrupted [35]. Thus,
malate induces a higher rate of oxygen consumption in Keap1-KD
compared to WT, but its effect is weaker in Nrf2-KO mitochondria.
Similarly, in the presence of rotenone (when complex I is inhib-
ited), succinate activates oxygen consumption to a greater extent
in Keap1-KD compared to WT, whereas the response in Nrf2-KO
mitochondria is diminished. In addition, Nrf2-KO primary neuro-
nal cultures and mice are more sensitive to the toxicity of the
complex II inhibitors 3-nitropropionic acid and malonate, whereas
intrastriatal transplantation of Nrf2-overexpressing astrocytes is
protective [48,49]. Similarly, Nrf2-KO mice are more sensitive to,
whereas genetic or pharmacological activation of Nrf2 has protec-
tive effects against, neurotoxicity caused by the complex I inhibitor
1-methyl-4-phenylpyridinium ion in the 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine animal model of Parkinson's disease
[49–61].
The respiratory control ratio (RCR), the ratio of State 3 (ADP-
stimulated) to State 4 respiration (no ADP present), is decreased in
the absence of Nrf2, but the RCR is similar between Keap1-KD and
WT mitochondria [35]. As the RCR is an indication of the degree of
coupling of the mitochondrial respiratory chain activity to oxida-
tive phosphorylation, this ﬁnding indicates that the higher rate of
respiration in Keap1-KD mitochondria is not due to uncoupling of
oxidative phosphorylation. It further suggests that oxidative phos-
phorylation is more efﬁcient when Nrf2 is activated. The higher
rate of respiration in Keap1-KD mitochondria is consistent with
the higher levels of mitochondrial ROS production [38] as higher
respiration rates may lead to increased electron leak. However,
under conditions of oxidative stress, the increased ROS production
is counteracted by the Nrf2-dependent transcriptional upregula-
tion of uncoupling protein 3 (UCP3), which increases the proton
conductance of the mitochondrial inner membrane and conse-
quently decreases the production of superoxide [62]. Very
recently, it was shown that the lipid peroxidation product 4-
hydroxy-2-nonenal mediates the Nrf2-dependent upregulation of
UCP3 in cardiomyocytes; this might be particularly important for
protection under conditions of oxidative stress such as those
during ischemia–reperfusion [63].
Nrf2 affects the efﬁciency of oxidative phosphorylation and the
synthesis of ATP
In agreement with the effect of Nrf2 on respiration, in brain and
liver mitochondria, Nrf2 deﬁciency results in a decreased efﬁ-
ciency of oxidative phosphorylation (as estimated by the ratio of
ADP to oxygen, which is consumed for ATP synthesis), whereas
Nrf2 activation (Keap1-KD) has the opposite effect [35]. Compared
to WT, the ATP levels are signiﬁcantly higher in cells with
constitutive upregulation of Nrf2 and lower when Nrf2 is knocked
down [64] or disrupted [35]. Furthermore, the use of inhibitors of
oxidative phosphorylation (oligomycin) or glycolysis (iodoacetic
acid) has revealed that Nrf2 changes the way by which cells
produce ATP. Thus, in WT neurons, oligomycin causes a complete
drop in ATP and iodoacetic acid has no further effect. Remarkably,
in Nrf2-KO cells, oligomycin increases the ATP levels, which are
then slowly, but completely, depleted by iodoacetic acid, indicat-
ing that in the absence of Nrf2, glycolysis, and not oxidative
phosphorylation, is the main source of ATP production. Interest-
ingly, despite the increased efﬁciency of oxidative phosphorylation
in Keap1-KD cells, addition of oligomycin results in an 80%
decrease in ATP levels, and iodoacetic acid causes a further 20%
decrease. Thus, either Nrf2 deﬁciency or its constitutive activation
reduces the contribution of oxidative phosphorylation and
increases the contribution of glycolysis toward the synthesis of
ATP. This effect is particularly pronounced when Nrf2 is absent and
is consistent with the dependence of the Δψm on the presence of
glucose in the medium [35] and the increased levels of glycolytic
intermediates (G-6-P, F-6-P, dihydroxyacetone phosphate, pyru-
vate, and lactate) after knockdown of Nrf2 [24].
The increase in ATP levels after inhibition of the F1F0-ATPase by
oligomycin indicates that in the absence of Nrf2, the F1F0-ATPase
functions as an ATPase and not an ATP synthase, i.e., it operates in
reverse. Such reversal in activity most likely reﬂects the need to
pump protons across the inner mitochondrial membrane in an
attempt to maintain the Δψm, which is crucial for the functional
integrity of this organelle. The reversal of the function of the F1F0-
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ATPase is also evidenced by the observed mitochondrial depolar-
ization upon oligomycin administration to Nrf2-KO cells, which is
in sharp contrast to the hyperpolarization occurring in their WT or
Keap1-deﬁcient counterparts [35]. Overall, it seems that under
conditions of Nrf2 deﬁciency ATP is produced primarily in glyco-
lysis, and this ATP is then used in part by the F1F0-ATPase to
maintain the Δψm.
Nrf2 enhances mitochondrial fatty acid oxidation
The effect of Nrf2 deﬁciency on the Δψm is particularly
pronounced when cells are incubated in medium without glucose,
and the Δψm is 50% lower in Nrf2-KO compared to WT cells
[35]. Under conditions of glucose deprivation, mitochondrial fatty
acid oxidation (FAO) is a major provider of substrates for respira-
tion and oxidative phosphorylation, suggesting that Nrf2 may
affect FAO. Indeed, the efﬁciency of FAO for both the long-chain
(C16:0) saturated fatty acid palmitic acid and the short-chain
(C6:0) hexanoic acid is higher in Keap1-KO MEFs and isolated
heart and liver mitochondria than in their WT counterparts,
whereas it is lower in Nrf2-KO cells and mitochondria [65]. These
effects are also highly relevant to humans: indeed, metabolic
changes indicative of better integration of FAO with the activity
of the TCA cycle have been reported to occur in human interven-
tion studies with diets rich in glucoraphanin, the precursor of the
classical Nrf2 activator sulforaphane [66].
During the ﬁrst step of mitochondrial FAO, the pro-R hydrogen
of the β-carbon leaves as a hydride that reduces the FAD cofactor
to FADH2, which in turn transfers electrons to ubiquinone (UbQ) in
the respiratory chain, ultimately contributing to ATP production.
Whereas stimulation of FAO by palmitoylcarnitine in the absence
of glucose causes the expected increase in the ATP levels in WT
and Keap1-KO cells, with the ATP rise being faster in Keap1-KO
cells, the identical treatment produces no ATP changes in Nrf2-KO
MEFs [65]. This experiment demonstrates that, in the absence of
Nrf2, FAO is suppressed, and furthermore, it implicates suppres-
sion of FAO as one of the reasons for the lower ATP levels under
conditions of Nrf2 deﬁciency [35,64].
Notably, human 293 T cells in which Nrf2 has been silenced
have a lower expression of CPT1 and CPT2 [67], two isoforms of
carnitine palmitoyltransferase (CPT), the rate-limiting enzyme in
mitochondrial FAO. In agreement, the mRNA levels of Cpt1 are
lower in livers of Nrf2-KO compared to WT mice [68]. CPT
catalyzes the transfer of the acyl group of a long-chain fatty
acyl-CoA from coenzyme A to L-carnitine and thus permits the
import of acylcarnitine from the cytoplasm into the mitochondria.
Although this has not been examined to date, it is possible that in
addition to the transcriptional effects on CPT1 expression, Nrf2
may also affect the function of this enzyme by controlling the
levels of its main allosteric inhibitor, malonyl-CoA. This is because,
by a mechanism that is currently unclear, Nrf2 regulates negatively
the expression of stearoyl CoA desaturase (SCD) [69] and citrate
lyase (CL) [69,70]. Curiously, knockout or inhibition of SCD leads to
increased phosphorylation and activation of AMP-activated pro-
tein kinase (AMPK) [71–73], and it can be speculated that, in the
absence of Nrf2, the SCD levels will increase, in turn lowering
AMPK activity. This could be further compounded by the reduced
protein levels of AMPK that have been observed in livers of Nrf2-
KO mice [68], a ﬁnding that is in close agreement with the
increased AMPK levels, which have been reported in livers of
Keap1-KD mice [74]. One consequence of the decreased AMPK
activity is the relief of its inhibitory phosphorylation (at Ser79) of
acetyl-CoA carboxylase (ACC) [75], which could be further tran-
scriptionally upregulated in the absence of Nrf2 because it is
downregulated by Nrf2 activation [70]. The high ACC activity, in
combination with the upregulated CL expression that will inc-
rease the production of acetyl-CoA, the substrate for ACC, may
ultimately increase the levels of the ACC product, malonyl-CoA.
The high levels of malonyl-CoA will inhibit CPT, thereby decreasing
the transport of fatty acids into the mitochondria. Finally, Nrf2
positively regulates the expression of CD36 [76], a translocase that
imports fatty acids across plasma and mitochondrial membranes.
Thus, one mechanism by which Nrf2 may affect the efﬁciency of
mitochondrial FAO is by regulating the import of long-chain fatty
acids into the mitochondria.
In addition to direct transcriptional regulation, Nrf2 may also
alter the efﬁciency of mitochondrial FAO by its effects on the
cellular redox metabolism. This may be especially relevant when
Nrf2 activity is low or absent, conditions that shift the cellular
redox status toward the oxidized state. Indeed, several FAO
enzymes have been identiﬁed as being sensitive to redox changes.
One such enzyme is very long-chain acyl-CoA dehydrogenase
(VLCAD), which contributes more than 80% to the palmitoyl-CoA
dehydrogenation activity in human tissues [77]. Interestingly,
Hurd et al. [78] have shown that VLCAD contains cysteine residues
that signiﬁcantly change their redox state upon exposure of
isolated rat heart mitochondria to H2O2. Additionally, S-
nitrosylation of murine hepatic VLCAD at Cys238 improves the
catalytic efﬁciency of the enzyme [79], and it is likely that
oxidation of the same cysteine may have the opposite effect,
ultimately lowering the efﬁciency of mitochondrial FAO. It is
therefore possible that, although the expression levels of VLCAD
are not signiﬁcantly different in WT, Nrf2-KO, or Keap1-KO MEFs
[65], the enzyme activity of VLCAD could be lower in the absence
of Nrf2 owing to the higher levels of ROS.
Based on all of these ﬁndings, it can be proposed that (Fig. 3): in
the absence of Nrf2, the NADPH levels are lower owing to
decreased expression of ME1, IDH1, G6PD, and PGD. The levels of
reduced glutathione are also lower owing to decreased expression
of enzymes that participate in its biosynthesis and regeneration
and the lower levels of NADPH that are required for the conversion
of the oxidized to the reduced form of glutathione. The low
expression of ME1 will decrease the pool of pyruvate entering
the mitochondria, with glycolysis becoming the major source of
pyruvate. The generation of NADH is slower, leading to impaired
activity of complex I and increased mitochondrial ROS production.
The reduction of FAD to FADH2 is also slower, at least in part owing
to less efﬁcient fatty acid oxidation, compromising the electron
ﬂow from FADH2 to UbQ and into complex III. As UbQH2 is an
activator of succinate dehydrogenase [80], slowing down its
formation may lower the enzyme activity of succinate dehydro-
genase. The increased levels of superoxide and hydrogen peroxide
can inhibit complex II activity further [81]. The lower efﬁciency of
fatty acid oxidation contributes to the decreased substrate avail-
ability for mitochondrial respiration and ATP production in oxida-
tive phosphorylation. As a compensatory mechanism, glycolysis is
enhanced. ATP synthase functions in reverse, as an ATPase, in an
attempt to maintain the Δψm.
Nrf2 and mitochondrial biogenesis
It has been reported that, compared to WT, the livers of Nrf2-
KO mice have a lower mitochondrial content (as determined by
the ratio of mitochondrial to nuclear DNA); this is further
decreased by a 24-h fast in both WT and Nrf2-KO mice; in contrast,
although no different from WT under normal feeding conditions,
the mitochondrial content in mice with high Nrf2 activity is not
affected by fasting [82]. Interestingly, supplementation with the
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Nrf2 activator (R)-α-lipoic acid [83–85] promotes mitochondrial
biogenesis in 3T3-L1 adipocytes [86]. Two classes of nuclear
transcriptional regulators play critical roles in mitochondrial
biogenesis. The ﬁrst class are transcription factors, such as nuclear
respiratory factors11 and 2, which control the expression of genes
encoding subunits of the ﬁve respiratory complexes, mitochon-
drial translational components, and heme biosynthetic enzymes
that are localized to the mitochondrial matrix [88]. Piantadosi
et al. [89] have shown that the Nrf2-dependent transcriptional
upregulation of nuclear respiratory factor 1 promotes mitochon-
drial biogenesis and protects against the cytotoxicity of the
cardiotoxic anthracycline chemotherapeutic agent doxorubicin. In
contrast, Zhang et al. [82] have reported that genetic activation of
Nrf2 does not affect the basal mRNA expression of nuclear
respiratory factor 1 in the murine liver.
The second class of nuclear transcriptional regulators with
critical functions in mitochondrial biogenesis are transcriptional
coactivators, such as peroxisome proliferator-activated receptor γ
coactivators (PGC)1α and 1β, which interact with transcription
factors, the basal transcriptional and RNA-splicing machinery, and
histone-modifying enzymes [88,90,91]. The expression of the
PGC1 family of coactivators is inﬂuenced by numerous environ-
mental signals. Treatment of human ﬁbroblasts with the Nrf2
activator sulforaphane causes an increase in mitochondrial mass
and induction of PGC1α and PGC1β [92], although the potential
dependence on Nrf2 was not examined in this study. However,
diabetic mice in which Nrf2 is either activated by Keap1 gene
hypomorphic knockdown (db/db:Keap1ﬂox/:Nrf2þ /þ) or dis-
rupted (db/db:Keap1ﬂox/:Nrf2 /) have lower hepatic PGC1α
expression levels than control animals (db/db:Keap1ﬂox/þ :Nrf2þ /þ)
[93]. No differences in the mRNA levels for PGC1α are seen in
livers of nondiabetic mice that are either WT or Nrf2-KO, whereas
these levels are lower in Nrf2-overexpressing (Keap1-KD and liver-
speciﬁc Keap1-KO) animals [82]. Notably, a 24-h fast increases the
levels of PGC1α mRNA in the livers of mice of all genotypes, but
the increase is signiﬁcantly greater in livers of Nrf2-KO compared
to WT or Nrf2-overexpressing mice. Compared to WT, Nrf2-KO
mice experiencing septic infection or acute lung injury due to
infection show attenuated transcriptional upregulation of nuclear
respiratory factor 1 and PGC1α [94,95]. Together, these observa-
tions suggest that the role of Nrf2 in maintaining the levels of both
nuclear respiratory factor 1 and PGC1α is complex and becomes
most prominent under conditions of stress.
In addition to expression of genes encoding mitochondrial
proteins, mitochondrial biogenesis requires the synthesis of
nucleotides. Genetic activation of Nrf2 enhances purine biosynth-
esis by upregulating the pentose phosphate pathway and the
metabolism of folate and glutamine, particularly in rapidly pro-
liferating cells (Fig. 2) [24]. Analysis of the transcriptome of mutant
Drosophila deﬁcient for the mitochondrial serine/threonine pro-
tein kinase PTEN-induced putative kinase 1 (PINK1) has shown
that mitochondrial dysfunction leads to the transcriptional upre-
gulation of genes affecting nucleotide metabolism [96], suggesting
that the enhanced nucleotide biosynthesis represents a mechan-
ism for protection against the neurotoxic consequences of PINK1
deﬁciency. Nrf2 regulates the expression of phosphoribosyl pyr-
ophosphate amidotransferase (PPAT), which catalyzes the entry
into the de novo purine nucleotide biosynthetic pathway, and
mitochondrial methylenetetrahydrofolate dehydrogenase 2 (MTHFD2)
(Fig. 2). The latter is a bifunctional enzyme with dehydrogenase and
cyclohydrolase activities that is critical in providing both glycine and
formate as sources of one-carbon units for purine biosynthesis in
rapidly growing cells [97]. It is therefore likely that Nrf2 activation
might be protective and might reverse mitochondrial dysfunction in
PINK1 deﬁciency. Indeed, pharmacological activation of Nrf2 by
sulforaphane, or the triterpenoid RTA-408, restores Δψm and protects
PINK1-deﬁcient cells against dopamine toxicity [98]. Although the
underlying mechanisms seem to be complex, together, these ﬁndings
indicate that Nrf2 activity may affect mitochondrial biogenesis by
inﬂuencing the expression levels of critical transcription factors and
coactivators, as well as by enhancing nucleotide biosynthesis.
Nrf2 and mitochondrial integrity
Although direct evidence is not always available, there are
strong indications that Nrf2 is important for mitochondrial integ-
rity, particularly under conditions of oxidative stress. Mitochondria
isolated from the brain and liver of rats that had been adminis-
tered a single dose of the Nrf2 activator sulforaphane are resistant
to opening of the mitochondrial permeability transition pore
(mPTP) caused by the oxidant tert-butylhydroperoxide [99,100].
The mPTP, a complex that allows the mitochondrial inner mem-
brane to become permeable to molecules with masses up to
1500 Da, was recently identiﬁed to be formed from dimers of the
F0F1-ATP synthase [101]. The sulforaphane-mediated resistance to
mPTP opening correlates with increased antioxidant defenses, and
the levels of mitochondrial GSH, glutathione peroxidase 1, malic
enzyme 3, and thioredoxin 2 are all upregulated in mitochondrial
fractions isolated from sulforaphane-treated animals [100].
Mitochondrial protein damage and impairment in respiration
caused by the electrophilic lipid peroxidation product 4-hydroxy-
2-nonenal are attenuated in mitochondria isolated from the
cerebral cortex of sulforaphane-treated mice [102]. In rat renal
epithelial cells and in kidney, sulforaphane is protective against
cisplatin- and gentamicin-induced toxicity and loss of Δψm
[103,104]. Protection against a panel of oxidants (superoxide,
hydrogen peroxide, peroxynitrite) and electrophiles (4-hydroxy-
2-nonenal and acrolein) and an increase in mitochondrial anti-
oxidant defenses have been also observed upon treatment of rat
aortic smooth muscle cells with sulforaphane [105]. In a model of
contrast-induced acute kidney injury, limb ischemic precondition-
ing was recently shown to have protective effects, including
inhibition of the opening of the mPTP and mitochondrial swelling,
by activation of Nrf2 consequent to the inhibition of GSK3β [106].
Mitophagy, the process by which dysfunctional mitochondria
are selectively engulfed by autophagosomes and delivered to
lysosomes to be degraded and recycled by the cell, is essential for
mitochondrial homeostasis [107,108]. Whereas no causative rela-
tion between Nrf2 and mitophagy has been established, there is
evidence that the transcription factor may be important in mito-
chondrial quality control by playing a role in mitophagy. This might
be especially prominent under conditions of oxidative stress. Thus,
in a model of sepsis, the increases in the levels of the autophago-
some marker MAP1 light chain 3-II (LC3-II) and the cargo protein
p62 at 24 h postinfection are suppressed in Nrf2-KO compared to
WT mice [109]. A small-molecule inducer of mitophagy (called p62-
mediated mitophagy inducer, PMI) was recently discovered; this
1,4-diphenyl-1,2,3-triazole compound was originally designed as an
Nrf2 activator that disrupts the interaction of the transcription
factor with Keap1 [110]. Similar to cells in which Nrf2 is genetically
upregulated (Keap1-KD or Keap1-KO), cells exposed to PMI have
higher restingΔψm. Importantly, the increase in mitochondrial LC3
localization that is observed after PMI treatment of WT cells does
not occur in Nrf2-KO cells, suggesting the involvement of Nrf2.
1 Unfortunately, the same abbreviation (NRF) is often used to indicate either
“nuclear respiratory factor” or “NF-E2 p45-related factor,” as pointed out by Baldelli
et al. [87]. Furthermore, there are examples in the literature in which this
abbreviation has been used erroneously. As the ﬁelds of Keap1–Nrf2 signaling
and mitochondrial biology converge, it is of utmost importance to maintain clarity.
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Last, ultrastructural analysis of liver sections has revealed the
presence of swollen mitochondria with reduced crista and dis-
rupted membranes in hepatocytes of Nrf2-KO, but not WT, mice
that had been fed a high-fat diet for 24 weeks; notably, these livers
show clear evidence of oxidative stress and inﬂammation [68]. It
can be concluded that Nrf2 has a critical role in maintaining
mitochondrial integrity under conditions of oxidative and inﬂam-
matory stress.
Concluding remarks
Although many questions still remain open, the available
experimental evidence clearly indicates that Nrf2 is an important
player in the maintenance of mitochondrial homeostasis and
structural integrity. This role becomes particularly critical under
conditions of oxidative, electrophilic, and inﬂammatory stress
when the ability to upregulate Nrf2-mediated cytoprotective
responses inﬂuences the overall health and survival of the cell
and the organism. The role of Nrf2 in mitochondrial function
represents another layer of the broad cytoprotective mechanisms
orchestrated by this transcription factor. As many human patho-
logical conditions have oxidative stress, inﬂammation, and
mitochondrial dysfunction as essential components of their patho-
genesis, pharmacological activation of Nrf2 holds promise for
disease prevention and treatment. Comprehensive understanding
of the precise mechanisms by which Nrf2 affects mitochondrial
function is essential for rational design of future clinical trials and
may offer new biomarkers for monitoring therapeutic efﬁcacy.
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